Antitumor activities of PSMA×CD3 diabodies by redirected T-cell lysis of prostate cancer cells

Immunotherapy

Volumn 5, Issue 1, 2013, Pages 27-38

  Baum, Volker ^a,b   Bühler, Patrick ^a   Gierschner, Dorothee ^a   Herchenbach, Dieter ^a   Fiala, Gina J ^b,c   Schamel, Wolfgang W ^b,c   Wolf, Philipp ^a   Elsässer Beile, Ursula ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

Author keywords

immunotherapy; prostate cancer; PSMA CD3 diabodies; T cell targeting

Indexed keywords

MONOCLONAL ANTIBODY; PROSTATE SPECIFIC MEMBRANE ANTIGEN CD3 DIABODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER CELL; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL VIABILITY; CONTROLLED STUDY; COVALENT BOND; CYTOLYSIS; CYTOTOXICITY; ESCHERICHIA COLI; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MALE; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; HUMANS; JURKAT CELLS; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, SCID; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SINGLE-CHAIN ANTIBODIES; TREATMENT OUTCOME;

EID: 84871546145     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.136     Document Type: Article

References (31)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011).
2. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J. Cell. Biochem. 91, 528-539 (2004).
3. Elsasser-Beile U, Buhler P, Wolf P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr. Drug Targets 10, 118-125 (2009).
4. Muller D, Kontermann RE. Bispecific antibodies for cancer immunotherapy: Current perspectives. BioDrugs 24, 89-98 (2010).
5. Volkel T, Korn T, Bach M, Muller R, Kontermann RE. Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies. Protein Eng. 14, 815-823 (2001).
6. Kontermann RE. Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol. Sin. 26, 1-9 (2005).
7. Wolf P, Alt K, Wetterauer D et al. Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer. J. Immunother. 33, 262-271 (2010).
8. Kipriyanov SM, Moldenhauer G, Martin AC, Kipriyanova OA, Little M. Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity. Protein Eng. 10, 445-453 (1997).
9. Schagger H, Cramer WA, von Jagow G. Analysis of molecular masses and oligomeric states of protein complexes by blue native electrophoresis and isolation of membrane protein complexes by two-dimensional native electrophoresis. Anal. Biochem. 217, 220-230 (1994).
10. Swamy M, Siegers GM, Minguet S, Wollscheid B, Schamel WW. Blue native polyacrylamide gel electrophoresis (BN-PAGE) for the identification and analysis of multiprotein complexes. Sci. STKE 345, pl4 (2006).
11. Wolf P, Gierschner D, Buhler P, Wetterauer U, Elsasser-Beile U. A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells. Cancer Immunol. Immunother. 55, 1367-1373 (2006).
12. Bühler P, Wolf P, Gierschner D et al. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells. Cancer Immunol. Immunother. 57, 43-52 (2008).
13. Kipriyanov SM, Moldenhauer G, Schuhmacher J et al. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J. Mol. Biol. 293, 41-56 (1999).
14. Baeuerle PA, Kufer P, Bargou R. Bi TE. Teaching antibodies to engage T cells for cancer therapy. Curr. Opin. Mol. Ther. 11, 22-30 (2009).
15. Bühler P, Molnar E, Dopfer EP et al. Target-dependent T-cell activation by coligation with a PSMAxCD3 diabody induces lysis of prostate cancer cells. J. Immunother. 32, 565-573 (2009).
16. Dreier T, Lorenczewski G, Brandl C et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int. J. Cancer 100, 690-697 (2002).
17. Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol. Immunol. 43, 763-771 (2006).
18. Hoffmann-Fezer G, Gall C, Zengerle U, Kranz B, Thierfelder S. Immunohistology and immunocytology of human T-cell chimerism and graft-versus-host disease in SCID mice. Blood 81, 3440-3448 (1993).
19. Tary-Lehmann M, Saxon A, Lehmann PV. The human immune system in hu-PBL-SCID mice. Immunol. Today 16, 529-533 (1995).
20. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat. Rev. Immunol. 7, 118-130 (2007).
21. Fortmuller K, Alt K, Gierschner D et al. Effective targeting of prostate cancer by lymphocytes redirected by a PSMAxCD3 bispecific single-chain diabody. Prostate 71, 588-596 (2011).
22. Schlereth B, Fichtner I, Lorenczewski G et al. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res. 65, 2882-2889 (2005).
23. Lutterbuese R, Raum T, Kischel R et al. T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proc. Natl Acad. Sci. USA 107, 12605-12610 (2010).
24. Herrmann I, Baeuerle PA, Friedrich M et al. Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3- bispecific antibody engaging human T cells. PLoS ONE 5(10), e13474 (2010).
25. Lutterbuese R, Raum T, Kischel R et al. Potent control of tumor growth by CEA/ CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. J. Immunother. 32, 341-352 (2009).
26. Amann M, Friedrich M, Lutterbuese P et al. Therapeutic window of an EpCAM/CD3- specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans. Cancer Immunol. Immunother. 58, 95-109 (2009).
27. Brischwein K, Schlereth B, Guller B et al. MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol. Immunol. 43, 1129-1143 (2006).
28. Dreier T, Baeuerle PA, Fichtner I et al. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/ CD3-bispecific single-chain antibody construct. J. Immunol. 170, 4397-4402 (2003).
29. Kipriyanov SM, Cochlovius B, Schafer HJ et al. Synergistic antitumor effect of bispecific CD19xCD3 and CD19xCD16 diabodies in a preclinical model of non-Hodgkin's lymphoma. J. Immunol. 169, 137-144 (2002).
30. Asano R, Sone Y, Makabe K et al. Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent. Clin. Cancer Res. 12, 4036-4042 (2006).
31. Hayashi H, Asano R, Tsumoto K et al. A highly effective and stable bispecific diabody for cancer immunotherapy: Cure of xenografted tumors by bispecific diabody and T-LAK cells. Cancer Immunol. Immunother. 53, 497-509 (2004).